ClinicalTrials.gg

Program

emoxypine succinate

Also written as “Mexidol” and “Mexidol (Ethylmethylhydroxypyridine Succinate)”.

Its studies are mostly in Ischemic Stroke · Cognitive Dysfunction · Glaucoma, Open-Angle · Ischemia · Attention Deficit Disorder with Hyperactivity, led by Pharmasoft.

Furthest: phase 4, since Jan 15, 20248 company-led studies, 1 open or runningNext primary completion: Apr 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pharmasoft81 open or runningphase 4since Jan 15, 2024May 31, 2016Apr 2027phase 4 · NCT07575984

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 31, 2016First study: phase 3 study in Ischemic StrokeFirst studyNCT02793687 · 150 enrolled · Russian Federation
  2. Jan 15, 2024Phase 4 study in Ischemic StrokeNCT06221826 · 60 enrolled · Russian Federation
  3. May 24, 2024Phase 3 study in Ischemic StrokeNCT06437626 · 304 enrolled · Kazakhstan, Russia, Uzbekistan
  4. Feb 11, 20252 phase 3 studiesNCT06854601, NCT06834490
  5. Mar 24, 2025Phase 2 study in Glaucoma, Open-AngleNCT06903156 · 102 enrolled · Russia
  6. May 4, 2026Phase 4 study in Ischemic StrokeNCT07575984 · 120 planned · Russia
  7. Jul 7, 2026Phase 4 study in Cognitive DysfunctionNCT07700615 · 120 enrolled · Russia

Ahead

  1. Apr 2027Primary completion: phase 4 study in Ischemic StrokeNCT07575984

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07700615Cognitive Dysfunction · Russia4CompletedNov 5, 2025120
NCT07575984Ischemic Stroke · Russia4RecruitingApr 2027120
NCT06903156Glaucoma, Open-Angle · Russia2CompletedSep 7, 2023102
NCT06854601Attention Deficit Disorder with Hyperactivity · Russia3CompletedJul 13, 2020333
NCT06834490Ischemia · Russia, Uzbekistan3CompletedDec 8, 2020318
NCT06437626Ischemic Stroke · Kazakhstan, Russia, Uzbekistan3CompletedAug 18, 2023304
NCT06221826Ischemic Stroke · Russian Federation4CompletedSep 12, 202360
NCT02793687Ischemic Stroke · Russian Federation3CompletedMay 27, 2016150

How it is read

Names in the registry

  • “Mexidol”, 7 entries
  • “Mexidol (Ethylmethylhydroxypyridine Succinate)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.